MERS-CoV vaccine
Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
1. A nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
(a) an immunogenic fragment of SEQ ID NO: 1, wherein the fragment encodes a sequence having 100% identity to consecutive amino acids over at least 60% of the full length of SEQ ID NO: 2;
(b) an immunogenic fragment of SEQ ID NO: 3, wherein the fragment encodes a sequence having 100% identity to consecutive amino acids over at least 60% of the full length of SEQ ID NO: 2;
(c) a nucleotide sequence having at least 90% identity over an entire length of the nucleic acid sequence set forth in SEQ ID NO: 1;
(d) a nucleotide sequence having at least 90% identity over an entire length of the nucleic acid sequence set forth in SEQ ID NO: 3;
(e) an immunogenic fragment of SEQ ID NO: 1, wherein the fragment comprises a sequence having 100% identity to consecutive bases over at least 60% of the full length of SEQ ID NO:1; and
(f) an immunogenic fragment of SEQ ID NO: 3, wherein the fragment comprises a sequence having 100% identity to consecutive bases over at least 60% of the full length of SEQ ID NO: 3.
2. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises an expression vector.
3. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is incorporated into a viral particle.
4. An immunogenic composition comprising the nucleic acid molecule of claim 1 .
5. The immunogenic composition of claim 4 , further comprising at least one selected from the group consisting of a pharmaceutically acceptable excipient and an adjuvant.
6. A method of inducing an immune response against a Middle East Respiratory Syndrome coronavirus (MERS-CoV) in a subject in need thereof, the method comprising administering the nucleic acid molecule of claim 1 to the subject.
7. The method of claim 6 , wherein administering includes at least one of electroporation and injection.
8. A method of protecting a subject in need thereof from infection with a Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering the nucleic acid molecule of claim 1 to the subject.
9. The method of the claim 8 , wherein administering includes at least one of electroporation and injection.
10. A method of treating a subject in need thereof against Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering the nucleic acid molecule of claim 1 to the subject, wherein the subject is thereby resistant to one or more MERS-CoV strains.
11. The method of claim 10 , wherein administering includes at least one of electroporation and injection.
12. A method of inducing an immune response against a Middle East Respiratory Syndrome coronavirus (MERS-CoV) in a subject in need thereof, the method comprising administering a peptide to the subject, wherein the peptide is selected from the group consisting of:
a) the peptide comprises an amino acid sequence as set forth in SEQ ID NO:2, and
b) the peptide comprises an amino acid sequence as set forth in SEQ ID NO:4.
13. The method of claim 12 , wherein administering includes at least one of electroporation and injection.
14. A method of protecting a subject in need thereof from infection with a Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering a peptide to the subject, wherein the peptide is selected from the group consisting of:
a) the peptide comprises an amino acid sequence as set forth in SEQ ID NO:2, and
b) the peptide comprises an amino acid sequence as set forth in SEQ ID NO:4.
15. The method of the claim 14 , wherein administering includes at least one of electroporation and injection.
16. A method of treating a subject in need thereof against Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering a peptide to the subject, wherein the peptide is selected from the group consisting of:
a) the peptide comprises an amino acid sequence as set forth in SEQ ID NO:2, and
b) the peptide comprises an amino acid sequence as set forth in SEQ ID NO:4,
wherein the subject is thereby resistant to one or more MERS-CoV strains.
17. The method of claim 16 , wherein administering includes at least one of electroporation and injection.